ClinicalTrials.gg
CompletedNCT00046462Updated Jan 11, 2011

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

A Phase 3 interventional study of Lantus (insulin glargine [rDNA origin] injection) and Metformin in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.

Enrollment
25th of 81
240 · median 80
Started
2001
with 1 other
Phase 3
25 of 81
none open now
Registered
1st of 81
by date
Lead sponsor
12 of 81
Sanofi

Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 25th largest by enrollment, is one of 2 that started in 2001, is one of 25 in phase 3, and was the 1st registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing Insulin Glargine in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 - 79 years of age
  • With diagnosed type 2 diabetes for at least a year treated with stable doses of two oral antidiabetic drugs of which one is either Avandia or Actos for at least three months

Exclusion criteria

Exclusion Criteria:

  • Major cardiovascular events

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants
06

What researchers measure

Primary outcomes

  1. To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy

    Time frame: During the Study Conduct

Secondary outcomes

  1. Occurrence of hypoglycemia

    Time frame: During the study conduct

  2. Change in fasting plasma glucose

    Time frame: During the study conduct

  3. Percentage of patients achieving HbA1C less than or equal to 7%

    Time frame: During the study conduct

  4. Time to glycemic control

    Time frame: During the study conduct

  5. Change in body weight

    Time frame: During the study conduct

  6. Change in serum lipid profile

    Time frame: During the study conduct

07

Study locations

1 site
  • Aventis
    Bridgewater, New Jersey 08807, United States
08

References and documents

Publications

  • Hollander P, Sugimoto D, Vlajnic A, Kilo C. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. J Diabetes Complications. 2015 Nov-Dec;29(8):1266-71. doi: 10.1016/j.jdiacomp.2015.05.022. Epub 2015 Jun 5. PubMed 26281972 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Nov 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2002
First posted
Oct 2, 2002
Start
Nov 2001
Primary completionActual
Nov 2004
CompletionActual
Dec 2004
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00046462
Lead sponsor
Sanofi
First posted
Oct 2, 2002
Start date
Nov 2001
Primary completion
Nov 2004
Completion
Dec 2004
Last update
Jan 11, 2011

Study contacts

Doug Green
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Metformin · 2,4-thiazolidinedione

Start the discussion